PRC-062

PRC-062 is an investigational controlled-release formulation of hydromorphone, a semi-synthetic opioid agonist, developed by Purdue Pharma (Canada). It was designed for the management of chronic non-cancer pain, utilizing a delivery system intended to provide sustained analgesia. The drug underwent Phase III clinical testing in Canada (ISRCTN54273961), where it was compared against an existing controlled-release hydromorphone product (Hydromorph Contin) to evaluate its efficacy and safety profile. Although the Phase III trial was completed in 2014, there has been no public evidence of regulatory submission or further clinical development since 2016, suggesting that the program is no longer being actively pursued.